Patrick P. Lally

OrbiMed Advisors LLC is an independent, SEC-registered investment advisor and hedge fund manager headquartered in New York City. It was founded by Sven Borho and Carl Gordon in 1989. The firm provides discretionary investment management services to US and non-US public and private funds.

Barclays Capital, Inc. is a registered broker/dealer headquartered in New York City. The firm was founded in 1997 and is a subsidiary of Barclays Group US, Inc., ultimately owned by Barclays plc (LON: BARC) in Great Britain. Barclays Capital provides large corporate, government and institutional clients a full spectrum of prime brokerage services which includes equities and fixed income financing, OTC Clearing, Futures and Foreign Exchange Prime Brokerage and access to industry insights and analytics from their Strategic Consulting team.

Red Mountain Capital Partners LLC (Red Mountain) is an alternative asset manager headquartered in Los Angeles, California. The firm was founded in 2005 and a subsidiary of Mesdag Family LP, which is principally owned by the Mesdag Family Trust. Red Mountain provides sound strategic advice to their portfolio companies to help drive long-term sustainable shareholder value.

Fortress Investment Group LLC provides investment management services. It specializes in asset-based investment, operations management, mergers and acquisitions, and capital markets. The company was founded by Wesley Robert Edens, Robert I. Kauffman, and Randal Alan Nardone in 1998 and is headquartered in New York, NY.

CorneaGen, Inc. engages in the provision of cornea care services. It offers precision cut corneal tissue, Descemet’s Membrane Endothelial Keratoplasty, and Descemet’s Stripping Automated Endothelial Keratoplasty. The firm's products include EndoSerter, Geuder Glass Cannula, and Donor Trephine Punch. The company was founded in 2016 and is headquartered in Seattle, WA.

Petrichor Healthcare Capital Management LP (Petrichor) is a private equity firm founded in 2016 by Tadd Wessel. The firm headquartered in New York.

Aurion Biotech, Inc. is a clinical-stage biotech company with offices in multiple locations. Aurion Biotech has initiated clinical trials in the US in 2023. The company is based in Seattle, WA. The company's mission is to restore vision to millions of patients with life-changing regenerative therapies. Aurion Biotech has received the prestigious Prix Galien award for best start-up in biotech. The company's first candidate is an off-the-shelf, clinically validated cell therapy for corneal care, which has received regulatory approval. The company is privately held and backed by leading investors, including Deerfield, Alcon, Petrichor, Flying L Partners, Falcon Vision/KKR, and Visionary Ventures. Greg Kunst has been the CEO of the company since 2021.